PharmaCorp Rx Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	24.08	20.89	5.79	-
Revenue Growth	145.63%	260.57%	-	-
Cost of Revenue	14.61	12.6	3.61	-
Gross Profit	9.47	8.3	2.18	-
Selling, General & Admin	9.42	8.19	3.2	0.58
Depreciation & Amortization Expenses	1.11	0.94	0.29	-
Other Operating Expenses	0.09	0.46	0.3	-
Total Operating Expenses	10.61	9.59	3.79	0.58
Operating Income	-1.14	-1.29	-1.6	-0.58
Interest Income	0.35	0.29	0.38	0.11
Other Non-Operating Income (Expense)	0.18	0.16	0.06	-
Total Non-Operating Income (Expense)	0.52	0.46	0.45	0.11
Pretax Income	-1.08	-0.84	-1.16	-0.47
Provision for Income Taxes	0.64	0.73	0.03	-
Net Income	-1.68	-1.42	-1.05	-0.47
Minority Interest in Earnings	0.07	0.06	-0.04	-
Net Income to Common	-1.62	-1.48	-1.01	-0.47
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	139	125	82	40
Shares Outstanding (Diluted)	142	125	82	40
Shares Change	37.71%	53.12%	102.90%	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-0.94	1.92	0.12	-0.52
Free Cash Flow Growth	-	1525.00%	-	-
Free Cash Flow Per Share	-0.01	0.02	0.00	-0.01
Gross Margin	39.32%	39.72%	37.69%	-
Operating Margin	-4.75%	-6.20%	-27.66%	-
Profit Margin	-6.96%	-6.81%	-18.14%	-
FCF Margin	-3.90%	9.18%	2.04%	-
EBITDA	-0.04	-0.35	-1.31	-0.58
EBITDA Margin	-0.16%	-1.70%	-22.65%	-
EBIT	-1.14	-1.29	-1.6	-0.58
EBIT Margin	-4.75%	-6.20%	-27.66%	-
Effective Tax Rate	-59.45%	-87.18%	-2.69%	0.00%